new oral glp 1 BREAKING: The FDA has approved the first GLP-1 pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill New oral GLP-1 drug helps

The primary pharmacodynamic distinctions between long-acting and short-acting GLP-1RAs are that long-acting agonists augment insulin production and suppress glucagon generation to lower postprandial glucose and fasting plasma glucose, while short-acting agonists chiefly lower postprandial glucose by delaying gastric emptying

Quick tip: check every combination tablet for duplicate active ingredients

If someone expects overnight visual change, they'll be disappointed

The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract

doi: 10.1111/j.1438-8677.2011.00464.x

10.1136/bmj.j5145 34